Neuland Laboratories Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/crvs07bf6oiv9tubmb2abkfa.pdf

Key Takeaways


CMS: The Mix Shift Driving Margins

Saharsh Davuluri: "If the drug, god forbid, doesn't do well, then we don't even see that business for a year, 2 years, 3 years. There's been cases where we never saw the business again after we made launch quantities."

Specialty & GDS: Resilience Despite Prime Product Decline


Development Revenue: The Quarter’s Wildcard

Saharsh Davuluri: "I think what might happen in one quarter is not necessarily going to repeat. But on an annualized basis, I think it's fair to surmise that this is a reasonable number."

Capacity, Capex & The Unit III Ramp

Saharsh Davuluri: "We're not necessarily saying that customers would fund the capex, but at least we would have enough business visibility, we would have enough conviction so that some of the challenges that Neuland had faced in the past of creating assets and then perhaps having to wait for an extended period of time, we are now in a better off position to avoid that end."

Cash Flow, Dividend & The Exceptional Advance


Organization, Risk & The Talent Build

Sucheth Davuluri: "currently, the primary focus of all the leadership of the organization is to build that depth in terms of the talent that we have in the organization."

Guidance & Commitments

CommitmentSpecificsTimeline
Growth measurementProgress should be measured on an annual basis, not quarterly, because growth is unlikely to be linear even annuallyOngoing
Unit III capacityHeadroom to grow through Unit III for a couple of years~2 years
Molecule commercialization2 molecules likely to become commercial next year; reasonable to expect at least 1 or 2 might drop out from the pipelineFY24
Cash flow normalizationExceptional advances of ₹135 crores expected to even outFY24
Capex disciplineNew manufacturing blocks only with enough business visibility and conviction to avoid idle assetsOngoing
Nomenclature changeDevelopment revenue classification will be tweaked to reduce confusionNo date

Key Metrics

MetricQ4 FY23
Total income₹415.1 cr, highest ever, +61% YoY
Gross margin54.1%, vs 47.9% in Q4 FY22 and 55.2% in Q3 FY23
Profit after tax₹84.5 cr, vs ₹21.8 cr in Q4 FY22
EPS₹65.9 per share
Full-year total income (FY23)₹1,200.9 cr, +26% YoY
Full-year EBITDA (FY23)₹281.1 cr, +94.8% YoY
Full-year EBITDA margin (FY23)23.4%, vs 15.1% in FY22, +830 bps
Free cash flow (FY23)₹172.4 cr
Net debt₹62.9 cr
Capex (FY23)₹66.1 cr
CMS revenue shareOver 45% of total revenues
Specialty revenueCrossed ₹100 cr
Active CMS projectsOver 85
DMFs filed during quarter3 (Tafamidis, Voxelotor, Voxelotor cocrystal)
Unit III capacity utilization~64% for FY23, expected at same level in FY24
Unit I and II capacity utilizationCloser to 80%, 90%
Dividend per share₹10, doubled from ₹5, highest ever
CMS molecules commercialized (since prior comment ~1.5 yrs ago)2
CMS molecules expected to commercialize next year2